GLP-1 Eye Warning

FDA Orders NAION Eye Warning on Ozempic, Zepbound and All GLP-1 Drugs: What Patients Should Know

Painted illustration of an unlabeled injection pen resting beside a pair of eyeglasses and an eye chart blurred beyond reading on a soft blue background
Illustration (AI-generated)

The U.S. Food and Drug Administration said Monday, Nov. 9, that every GLP-1 medication on the market must carry a new label warning about a potential increased risk of a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION.

The requirement covers the best-known weight-loss and diabetes drugs, including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, plus older GLP-1 diabetes medicines, NBC News reported. The FDA is directing drugmakers to add the information to the “Warnings and Precautions” section of their labels.

This article is general information, not medical advice. Don’t stop or change a prescription without talking to your health care professional.

What is NAION?

According to the FDA, NAION is a rare condition caused by decreased blood flow to the front part of the optic nerve, known as the optic disc. It can cause sudden, painless loss of vision in one eye, and that loss can be permanent.

NBC News noted there is no known treatment, and ABC News reported there is currently no known way to reverse the vision loss. The American Academy of Ophthalmology describes NAION as the second most common optic nerve disease in the U.S., occurring in up to 10 of every 100,000 people over 50, per NBC News.

The FDA says the underlying cause isn’t fully understood. Risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Someone who has had NAION in one eye faces a higher risk in the other eye.

Which drugs are covered by the GLP-1 eye warning?

The FDA’s list of approved GLP-1 receptor agonists includes:

  • Semaglutide: Ozempic, Wegovy, Rybelsus
  • Tirzepatide: Mounjaro, Zepbound (tirzepatide also acts on a second hormone receptor, GIP)
  • Liraglutide: Victoza, Saxenda, and Xultophy (with insulin degludec)
  • Dulaglutide: Trulicity
  • Lixisenatide: Soliqua (with insulin glargine)
  • Orforglipron: Foundayo, approved in 2026
  • Exenatide: generic versions (the Byetta brand application was withdrawn, not for safety reasons, the agency said)

How big is the risk?

The FDA describes the risk as “potential” and the condition as rare. Its findings rest on several lines of evidence:

  • Clinical trials: A meta-analysis of 126 randomized trials with more than 134,000 patients found 15 probable NAION cases: 10 among GLP-1 users and five among placebo recipients. That works out to 6.4 cases per 100,000 person-years on GLP-1 drugs versus 3.8 for comparison groups.
  • Real-world data: In an FDA Sentinel study of adults with Type 2 diabetes, there was no statistically significant difference between GLP-1 drugs and SGLT-2 inhibitors, but a higher risk was seen compared with DPP-4 inhibitors.
  • Published studies: The FDA said the most rigorous observational studies consistently found an increased risk in Type 2 diabetes patients starting GLP-1 drugs versus those other diabetes drugs.

The agency also said it could not identify a mechanism in animal data that would explain how the drugs might raise NAION risk, and that adverse-event reports were hard to interpret because NAION risk factors overlap with conditions common in GLP-1 patients. NAION cases have been reported with all currently marketed GLP-1 products.

The review began after a 2024 JAMA Ophthalmology study linked semaglutide prescriptions to higher NAION risk. NBC News reported that study found diabetes patients prescribed semaglutide were four times as likely to develop NAION; the FDA said it identified several limitations in that study but judged that further review was warranted.

What drugmakers say

The companies are not on the same page as the agency about causation. Novo Nordisk told ABC News that “the data do not establish a cause-and-effect relationship” and that it remains confident in the benefit-risk profile of its GLP-1 medicines. An Eli Lilly spokesperson told ABC News the FDA’s communication “does not reference any findings specific to Lilly medicines” and that the company is evaluating the update. Spokespeople for both companies told NBC News patient safety is their top priority.

NAION symptoms to watch for

The FDA lists these warning signs:

  1. Sudden, painless vision loss in one eye, sometimes noticed on waking
  2. Blurred or missing parts of vision, such as blind spots or tunnel vision
  3. Colors that look distorted
  4. Reduced central sharpness, such as blurry or hazy spots

The agency says patients should contact a health care professional right away if they notice any of these. Patients who have had NAION should talk with their clinician about whether to continue or stop their GLP-1 medicine. The FDA tells doctors to refer suspected cases promptly to an ophthalmologist and to consider stopping the drug unless the benefits clearly outweigh the risk.

Should patients stop taking Ozempic or Zepbound?

The FDA did not tell patients to stop. Dr. Manjot Gill, an ophthalmologist at Northwestern Medicine, told NBC News the warning was appropriate but that there is little cause for immediate anxiety. “We don’t want patients to really get overly concerned and anxious and to stop these medications,” she said, adding that the warning helps people know to see an eye provider if their vision changes.

FAQ

Does Ozempic cause blindness?

The FDA says there is a potential increased risk of NAION, a rare condition that can cause permanent vision loss in one eye. It has not established that the drugs cause it, and Novo Nordisk disputes a cause-and-effect link.

Does the warning apply to Zepbound and Mounjaro?

Yes. The requirement applies to all GLP-1 drugs, including tirzepatide.

How do I report a side effect?

The FDA accepts reports online through MedWatch or by phone at 1-800-332-1088.

Sources